Veeva Systems: Vertical SaaS Quality in Life Sciences
From Salesforce-Powered CRM to Independent Vault Platform — A Deep Dive into Durable Growth, Moats, and Valuation ($VEEV).
Welcome to Compound & Fire, where we’re on a mission to build wealth the smart way, hunting for top-quality businesses that grow shareholder value over the long haul, paving the road to financial freedom and early retirement.
This community is free, but if you’re enjoying the deep dives and want to fuel more, you can treat me to a coffee on Buy Me a Coffee. Every bit helps keep the fire burning, and I’m truly grateful for your support!
Come join the conversation on our Global Quality Investing Discord App here and hop on board my Substack for free if you haven’t yet. Let’s grow this journey together!
Introduction
This is the first article from the new Collective Fire Framework initiave. Member TuDi main contributor to this article, but it has been reviewed by other members including myself. TuDi is the creator of the F.L.O.W method of stock investing - using the power of awareness, patience and disciplined movement, just like in martial arts, in order to strike at high-conviction momentum plays and flow like fast rising water into long-term compounding businesses and ETFs. You can follow TuDi here.
Quick Scan
Last week I shared the Quick Scan of Veeva. It shows an Investment Readiness Score of 81.3, which makes it ready for a deep dive.
History of the Business
Veeva Systems Inc. is one of the most significant software success stories of the past two decades, a company that has managed to carve out a specialized yet enormous market in cloud-based software for life sciences. The firm was incorporated in 2007 under the name Verticals onDemand, Inc., later adopting the Veeva Systems name in April 2009 as its ambitions broadened.
From its earliest days, the company was positioned to exploit a gap in the market: while Salesforce and other horizontal SaaS providers offered platforms applicable to many industries, life sciences had unique compliance, regulatory, and workflow needs that were poorly served by generalist solutions. Veeva’s founders, led by current CEO Peter Gassner, a veteran of both Salesforce and PeopleSoft, saw the opportunity to build purpose-built cloud applications for pharmaceutical and biotech customers.
Gassner’s experience at Salesforce was pivotal. He had been one of the architects of the Salesforce platform, and he recognized both the power of multi-tenant cloud infrastructure and the limitations of a one-size-fits-all product. Life sciences stood out as a vertical requiring strict regulatory compliance, audit trails, and a heavy dose of content management in addition to customer relationship management.
By tailoring Salesforce’s technology to these requirements, Veeva quickly established itself as the go-to solution for pharma salesforces who needed to manage physician interactions within the tight confines of healthcare compliance.
The company’s first product, Veeva CRM, launched in 2007, was essentially a life sciences–specific CRM built on Salesforce’s Force.com platform. It immediately gained traction among pharmaceutical firms that were under increasing scrutiny to document interactions with healthcare providers. Within a few years, Veeva was serving several of the largest global pharma companies, a base that provided both credibility and recurring revenue stability.
Historical Evolution
Veeva Systems’ trajectory since its founding in 2007 offers a rare example of a vertical SaaS business that has scaled globally while retaining focus and discipline. The company was born during a period when cloud computing was still in its early adoption phase, especially in regulated industries like life sciences.
From the beginning, founder Peter Gassner positioned Veeva not as a broad-based enterprise software vendor, but as a specialist: the company would build mission-critical applications for pharmaceutical and biotech companies, tightly integrated with industry workflows, and delivered entirely via the cloud. This focus distinguished Veeva from generic CRM platforms and gave it an immediate identity in a crowded market.
Expansion into Content Management
Recognizing the limits of building on another company’s platform, Veeva soon began developing its own. In 2011, it launched Veeva Vault, a cloud-based enterprise content management platform designed specifically for regulated industries. Vault provided life sciences companies with tools to manage documents, workflows, clinical trial data, regulatory submissions, and quality processes.
This move proved transformative. Vault diversified Veeva away from reliance on Salesforce infrastructure and positioned the company as not just an application provider, but as the owner of a proprietary, extensible platform. Over the years, Vault became the anchor of Veeva’s business model and remains its most important growth engine today.
The life sciences industry encompasses pharmaceuticals, biotech, medical devices, diagnostics, and related fields where the stakes are especially high: long development cycles, rigorous regulatory oversight, and complex multi-stakeholder engagement (doctors, hospitals, payers, regulators, patients). In this context, a CRM specialized for life sciences becomes critical: unlike generic CRMs, it embeds features for regulatory compliance (e.g., tracking consent, audit trails, adverse event reporting), multichannel and omnichannel interactions with healthcare professionals (HCPs), and integration with scientific/clinical data systems.
Veeva is a leading example of such specialization: its Veeva CRM / Vault CRM is built specifically for life sciences, offering capabilities like approved email (to stay compliant), integrated field team management, consent management, and purpose-built engagement tools for medical science liaisons and commercial reps.
Because the life sciences domain requires both deep domain knowledge and strict compliance, CRM specialization matters. It enables firms to manage relationships and data without risking regulatory violations, while supporting high-value interactions across the scientific and commercial lifecycle.
IPO and Public Market Entry
By 2013, Veeva’s revenue was approaching $130 million, and the business was growing at more than 50% annually. In October of that year, the company went public on the New York Stock Exchange under the ticker VEEV. The IPO was a resounding success, raising $261 million at a valuation above $4 billion. An extraordinary multiple that reflected both Veeva’s growth and its unusually high margins for an enterprise software company. Investors were drawn to the combination of sticky, regulated-industry customers and the recurring revenue model of SaaS.
The IPO also marked the beginning of a new era of financial transparency, giving outsiders a clearer look into Veeva’s economics: gross margins in the 70% range, operating margins north of 20%, and free cash flow margins that would only expand over time. From its first years as a public company, Veeva set itself apart as both a growth stock and a highly profitable enterprise.
Broadening the Portfolio
Following the IPO, Veeva embarked on a decade-long expansion of its offerings. It built out the Veeva Commercial Cloud suite, which extended CRM into medical affairs, content management, and multichannel marketing. Products like Veeva CLM (closed-loop marketing), Veeva Align (territory alignment), and Veeva Network (customer master data) deepened its entrenchment within customer workflows.
Simultaneously, Vault expanded into multiple domains: Vault Clinical, Vault Quality, Vault Regulatory, and Vault Safety each targeted specific pain points in the drug development and commercialization process. By 2020, Veeva was serving not only commercial sales teams but also R&D organizations, regulatory departments, and quality assurance groups across the life sciences industry. This diversification insulated the company from cyclicality in any one part of the pharma value chain and broadened its total addressable market (TAM) into the tens of billions.
Financial Growth and Global Reach
From fiscal 2014 through fiscal 2025, Veeva’s revenues grew from roughly $130 million to nearly $3 billion, a compound annual growth rate exceeding 20% over more than a decade. Profitability kept pace: net margins are consistently above 25%, and free cash flow margins hover around 40–45%, metrics that place Veeva among the most efficient software businesses globally. The company now employs more than 7,000 people worldwide and serves customers in North America, Europe, Asia-Pacific, and Latin America, with more than 1,000 life sciences clients including 19 of the top 20 global pharmaceutical firms.
Early Growth and Salesforce Partnership
In its first decade, Veeva leveraged Salesforce’s Force.com platform to build Veeva CRM. This allowed the company to reach the market faster, reduce upfront infrastructure needs, and piggyback on Salesforce’s reliability. The partnership was both a blessing and a constraint: it accelerated adoption but created customer perception that Veeva was a “layer” rather than a platform in its own right. Nonetheless, Veeva quickly became the de facto standard CRM for pharmaceutical field sales representatives, gaining more than half of the market share among large pharma within five years of launch.
By 2013, when Veeva went public, revenue had reached $213 million, growing at over 60% annually. The IPO highlighted Veeva’s unusual profitability for a SaaS company, operating margins were above 20% even at that stage. Investors rewarded this combination of growth and profitability with one of the most successful SaaS debuts of that era.
Vault and Diversification
The next major evolution came with Veeva Vault, launched in 2011. Vault was a bold step: a fully independent cloud content management platform designed specifically for regulated documents and workflows. Unlike CRM, which had competitors, Vault addressed white space. The need for managing clinical trial data, regulatory submissions, and quality documentation in a compliant, secure, and auditable way. Over time, Vault became the growth engine of the company, expanding into dozens of modules across clinical, regulatory, quality, safety, and commercial domains.
This transition marked Veeva’s shift from being seen as “Salesforce for pharma” to an independent software platform with its own technical foundation. It also enabled expansion beyond commercial functions into research and development, a much larger addressable market.
The story of Veeva’s evolution is one of deliberate focus, disciplined execution, and widening competitive advantage. From a single CRM application built on someone else’s platform, it has grown into a diversified, independent ecosystem for regulated industries. Each stage of this evolution, from IPO, Vault expansion, diversification to Salesforce independence, reinforced its reputation as one of the most durable and predictable business models in enterprise software.
Management
Founding Leadership
Veeva Systems has been led since its founding by Peter P. Gassner, who remains both CEO and Chairman of the Board. Gassner’s longevity in the role is unusual for a modern software company; many firms see turnover at the top once they reach scale, but his continued presence reflects the founder-driven culture at Veeva. Gassner brings deep credibility, having previously served as SVP of Technology at Salesforce, where he was responsible for the Force.com platform, and earlier as Chief Architect of PeopleSoft. His combination of technical expertise and vision for vertical SaaS has anchored Veeva since 2007.
Alongside Gassner, co-founder Matt Wallach played a crucial role in the company’s early commercialization. Wallach served as President until his retirement from day-to-day duties, though he remains on the Board of Directors. This continuity ensures that the company retains the founding DNA even as it professionalizes its operations for long-term scale.
Executive Team Today
As of 2025, Veeva’s management team reflects a balance of long-tenured insiders and newer additions brought in to strengthen finance and operations. The key executives include:
Peter Gassner (CEO & Chairman): Founder, architect of the strategic roadmap, and holder of over 15 million shares (~9% of outstanding), giving him significant skin in the game.
Brian Van Wagener (CFO): Appointed in 2024 after the departure of longtime CFO Brent Bowman. Van Wagener joined as EVP of Finance in mid-2024, quickly elevated to CFO in September. His compensation reflects both base salary and substantial equity incentives with multi-year vesting, designed to ensure stability in the finance function.
Thomas D. Schwenger (President & Chief Customer Officer): Oversees field operations, customer success, and services. Schwenger plays a central role in ensuring the “land and expand” strategy succeeds across Veeva’s global client base.
E. Nitsa Zuppas (President & Chief of Staff): A cultural leader within the company, responsible for branding, people, and operational alignment across business units.
Josh Faddis (General Counsel): Senior Vice President and Corporate Secretary, bringing governance discipline to a company serving heavily regulated industries.
This team collectively combines industry-specific expertise, technical depth, and operational execution, though Gassner remains the indispensable leader.
Board of Directors
The board includes experienced industry veterans and investors. Gordon Ritter of Emergence Capital, one of the earliest venture investors in SaaS, has long been a key director. Independent directors such as Mary Lynne Hedley and Priscilla Hung add domain knowledge in biotech and enterprise software, respectively. Overall, the board balances founder influence with independent oversight, though Gassner’s dual role as CEO and Chairman consolidates power in management.
Executive Compensation
Veeva’s executive compensation philosophy diverges from the cash-heavy approaches common in Silicon Valley. According to the 2025 proxy (DEF 14A), all executive officers receive the same base salary—$450,000 in fiscal 2025, moving to $475,000 in 2026. Notably, there are no cash bonuses or short-term incentive plans. Instead, compensation is equity-driven, with two main vehicles:
Annual RSU “Stock Bonus”: Designed to provide near-term equity vesting aligned with base salary multiples (125%–375%). These vest quarterly over one year.
Annual Stock Options: Multiples of the RSU grants (3x–4x), vesting over four years. Options inherently tie compensation to long-term shareholder value.
For example, CFO Van Wagener received ~$3.9 million in combined RSUs and options in 2025. General Counsel Faddis received ~$3.2 million. The largest award went to Gassner, with a five-year stock option program approved in 2024 covering 2.65 million shares, vesting through 2030. Its grant-date fair value was ~$172 million, though the board noted the cost should be considered across five years, not one.
This structure strongly emphasizes long-term alignment and discourages short-term risk-taking. The lack of cash bonuses is unusual but reinforces Veeva’s disciplined culture.
SBC as % of Revenue
Last 5-year average: ~15.5% of revenue
Trend: Stable to slightly down versus the last years. SBC has not ballooned with scale, but remains high in absolute terms (~$450–470M/year).
Why It Matters
SBC dilutes intrinsic returns: while GAAP treats it as a non-cash expense, it represents future share dilution that reduces per-share FCF growth.
Adjusted FCF margins (excluding SBC) look ~45%, but owner’s earnings after SBC are closer to 30–32%.
This difference is key when modeling DCF or calculating a “true” FCF yield.
Insider Ownership
Founder ownership remains significant. Gassner controls ~9.1% of common stock, giving him influence over both governance and strategic direction. Directors and executives as a group own ~10.3%. Outside institutions such as Vanguard (8.1%) and BlackRock (5.7%) provide further oversight, though the founder’s stake ensures his interests are tightly linked to shareholders.
Credibility and Track Record
The management team has generally delivered on its commitments. Historical revenue and EPS guidance have been conservative and consistently exceeded.
Execution on Vault and expansion into new segments has validated the long-term strategy. The key open question remains the CRM migration off Salesforce, which will test both operational credibility and customer trust. Still, investor confidence is supported by the alignment of equity-heavy compensation, insider ownership, and a demonstrated ability to grow revenue >20% CAGR while maintaining >25% net margins.
Culture
Values and Philosophy
Veeva Systems has cultivated a culture that diverges from many Silicon Valley peers. While most high-growth software companies emphasize aggressive growth targets and cash-based incentives, Veeva’s leadership has consistently promoted a long-term, team-first philosophy. Founder and CEO Peter Gassner has been explicit in interviews and annual reports: the company is designed to be “built to last” rather than optimized for short-term performance. This vision has manifested in how the company treats employees, manages incentives, and positions itself within the broader community of stakeholders.
The executive compensation structure reflects these values. As outlined in the 2025 proxy statement, executives receive identical base salaries and are not eligible for cash bonuses. Compensation is largely equity-based, vesting over multiple years, reinforcing a patient, ownership-oriented mindset. This design cascades down into the culture at large: employees are encouraged to think like owners, not short-term contractors chasing quarterly metrics.
Employee Experience
Glassdoor and Indeed reviews consistently highlight high job satisfaction, with employees citing strong leadership, a clear mission, and meaningful work as top reasons for staying. As of 2025, Veeva maintains a rating above 4.0/5.0 on major employment platforms. Reviewers frequently point to the balance between performance expectations and work-life flexibility. Unlike some software companies that glorify burnout, Veeva emphasizes sustainable output and longevity.
Retention rates are strong: voluntary attrition is lower than industry averages in enterprise SaaS. Employees often cite the ability to work on critical systems in life sciences, such as clinical trial management and regulatory filing platforms, as a motivator, since their work contributes to bringing new medicines to market. This sense of purpose bolsters morale and aids recruitment.
Diversity and Inclusion
Veeva has made progress in diversity, equity, and inclusion (DEI), though like many technology firms, it still faces challenges. The company reports gender diversity figures in its workforce and leadership, with women comprising over 30% of employees and growing representation at senior levels. Initiatives aimed at building inclusive hiring pipelines, particularly for technical roles, are underway. Compared with peers, Veeva’s DEI efforts are notable for their integration into core business rather than being treated as peripheral HR projects. For instance, its Vault Quality and Regulatory products require close collaboration with global clients, naturally exposing teams to diverse perspectives.
Training and Development
Employee development is another pillar of culture. Veeva invests in training programs designed to help employees understand both technology and the life sciences domain. This dual expertise is essential, as the company’s products intersect deeply with scientific, regulatory, and commercial processes. Professional growth is not limited to technical skills; Veeva emphasizes leadership training, often promoting from within for senior roles. This has created continuity and stability in the workforce.
Cross-Domain Training Is Uncommon
Most SaaS companies train employees primarily in technical or product knowledge. Veeva, however, deliberately cross-trains staff in both software and life sciences ensuring engineers, product managers, and customer success teams understand FDA compliance, GxP validation, and clinical trial workflows.
This is unusual because:
Most competitors (e.g., Salesforce Health Cloud, Oracle Health) rely on domain specialists at the client to bridge that knowledge gap.
Veeva embeds this dual expertise internally, which enhances credibility with regulated customers and speeds implementation cycles.
Internal Promotion and Long Tenure
Veeva’s emphasis on leadership development and internal promotion has yielded one of the lowest voluntary turnover rates in the SaaS industry (~10–12% vs. sector median ~15–18%).
Many of its senior executives, including key figures in Vault, Commercial Cloud, and Regulatory, have risen internally over a decade.
This continuity supports Veeva’s “customer partnership” model: clients work with the same trusted individuals for years, creating institutional memory and long-term loyalty.Strategic Advantage: “Embedded Domain Knowledge”
This training culture translates directly into product quality and customer stickiness. When product managers and engineers understand the compliance constraints of pharma and biotech, they design features proactively for regulatory needs, reducing rework and improving speed to market.
In short, Veeva’s talent model itself is a moat: it’s expensive and time-consuming for competitors to replicate because it requires deep domain immersion, not just software know-how.
Peer Comparison
Alignment with Long-Term Thinking
One of Veeva’s most unique cultural commitments is its Public Benefit Corporation (PBC) status, adopted in 2021. As a PBC, Veeva is legally obligated to balance shareholder interests with those of employees, customers, and society. This choice, rare among public companies, codifies the cultural philosophy that the company’s purpose extends beyond maximizing quarterly earnings. It aligns with decisions such as resisting cash bonuses for executives and focusing on sustainable business practices. For employees, this reinforces the perception that they are working for a mission-driven company rather than a purely profit-maximizing entity.
A natural question is: what happens after the founder leadership? Veeva’s Board explicitly retains responsibility for CEO succession planning and monitors succession readiness for key roles. The recent 2024 performance option grant for Gassner vests over five years, contingent on his continued role as CEO through 2030, signaling long-term commitment to stability and alignment. Maintaining the cultural ethos post-founder is an underappreciated but critical execution risk.
Industry Comparisons
Relative to peers like Salesforce, Workday, or ServiceNow, Veeva’s culture appears more deliberately restrained and mission-centric. The absence of lavish perks or short-term incentives is unusual, but it fits the company’s strategy of serving heavily regulated, risk-averse clients. Employees are drawn to the stability and seriousness of purpose, rather than the hype-driven cycles that characterize much of Silicon Valley. This has created an identity distinct from general enterprise SaaS firms.
Risks in Cultural Evolution
That said, maintaining culture at scale is a challenge. With over 7,000 employees across multiple continents, local variations inevitably emerge. Growth beyond life sciences into adjacent industries may strain the cultural fabric, as teams accustomed to one domain are asked to adapt to new contexts. Moreover, reliance on equity-based compensation requires stock performance to remain strong; prolonged stagnation in share price could weaken morale if employees perceive their equity awards as less valuable.
Summary of Culture
Overall, Veeva’s culture can be described as long-term, ownership-driven, and purpose-led. The company avoids short-term gimmicks in favor of equity alignment, emphasizes employee well-being and mission orientation, and has codified its stakeholder commitments through PBC status. For investors, this culture reduces the risk of reckless decision-making but raises the question of whether slower, more deliberate growth might occasionally cause the company to miss near-term opportunities. Still, the cultural model has been a major contributor to the company’s remarkable financial consistency and employee loyalty.
Business model
Overview
Veeva Systems is a vertical SaaS company focused on cloud-based solutions for the life sciences industry. Unlike horizontal software firms that attempt to serve a wide range of industries with generic products, Veeva specializes in a single, highly regulated vertical where compliance, data integrity, and specialized workflows matter as much as functionality. This strategic choice underpins the stickiness of Veeva’s offerings, which are deeply embedded in critical processes like clinical trials, regulatory filings, and customer engagement.
At its core, Veeva’s business model is built on three pillars:
Subscription-based revenue (~80–85% of total), providing recurring and highly predictable cash flows.
Professional services (~15–20%), primarily implementation and training, designed not as profit centers but as enablers of product adoption.
Expansion across the pharma value chain, moving from sales and marketing (Commercial Cloud) into R&D, regulatory, and quality (Vault), and more recently into data analytics (Link and Data Cloud).
Gross margins in the mid-70s, operating margins near 30%, and free cash flow margins above 40% highlight the efficiency of this model. Unlike many SaaS peers, Veeva combines high growth with unusually high profitability.
Over 80–85% of revenue comes from multi-year contracts for software modules within Veeva Commercial Cloud and Veeva Vault. These contracts are sticky, mission-critical, and typically expand as customers roll out additional modules or increase usage.
The result is net revenue retention consistently above 120%, which means Veeva grows even before adding new customers.
Commercial Cloud
Veeva’s first business line, Commercial Cloud, remains foundational. It includes:
Veeva CRM: the flagship product, built initially on Salesforce, tailored to track pharma salesforce interactions with healthcare providers. It enforces compliance in physician outreach, samples distribution, and communications.
Veeva Medical CRM (Customer Relationship Management) and Veeva CLM (Closed Loop Marketing): tools for digital content delivery to physicians, particularly important as pharma interactions moved from in-person to digital channels post-COVID.
Veeva CRM Engage and Approved Email: virtual engagement modules, now indispensable in hybrid salesforce models.
Veeva Align and Events Management: territory alignment and meeting management solutions that integrate directly into CRM.
Veeva Nitro: a commercial data warehouse that integrates with CRM workflows.
Commercial Cloud has historically accounted for ~40% of revenue, though this share is gradually declining as Vault expands. Growth here is slower (mid-single digits), reflecting the maturity of CRM. However, switching costs remain formidable: once a global pharma’s 50,000+ field reps are on Veeva CRM, moving off would disrupt regulatory compliance.
Vault
The Vault platform is the crown jewel. It has become Veeva’s growth engine, expanding far beyond content management into dozens of specialized applications. Vault now contributes more than half of total revenue and is expected to dominate growth over the next decade. Key modules include:
Vault Clinical: manages trial master files, study start-up, and site document exchange. Clinical operations are highly regulated; Vault ensures compliant record-keeping and faster trial execution.
Vault Regulatory: supports regulatory submission workflows and electronic common technical documents (eCTDs) for global drug approvals.
Vault Quality: quality management systems (QMS) for manufacturing and laboratory processes, ensuring compliance with FDA and EMA standards.
Vault Safety: pharmacovigilance, tracking adverse events post-launch to comply with safety reporting requirements.
Vault is mission-critical. Once trial data, regulatory filings, and quality systems are embedded, customers cannot realistically switch providers without risking compliance failures and delays in product approvals. This gives Vault extraordinary stickiness and pricing power. Growth here is in the mid-teens to 20% range, and the TAM remains massive.
Data Cloud and Link
In recent years, Veeva has moved into data and analytics.
Veeva Data Cloud: a patient and physician longitudinal data platform, competing with IQVIA’s massive datasets. While still in early stages, this could become a multi-billion-dollar line if it captures share.
Veeva Link: maps scientific and medical expert networks, enabling pharma to identify key opinion leaders for clinical trials and product launches.
These products extend Veeva’s reach from workflows into insight generation, potentially raising average contract value (ACV) per client. Adoption is still ramping, but customer logos like Gilead suggest traction.
Professional Services
Professional services account for ~15% of revenue, with gross margins closer to breakeven. These services, implementation, data migration, and training, are designed to accelerate product adoption, not to generate profits. By keeping services pricing reasonable, Veeva lowers barriers for customers to deploy new modules. Importantly, services revenue is a leading indicator of subscription growth.
Case Study: Atlantic Research Group (ARG)
“Now, when sponsors ask us to add different types of documentation at the end of studies, we can easily accommodate the requests with minimal effort.” — David Tyson, Clinical Operations Manager, ARG
ARG, a contract research organization (CRO), adopted Veeva eTMF and Veeva CTMS to streamline its clinical operations.
Before adoption, ARG faced fragmented trial documentation, delays in trial master file workflows, and inefficient site communications across multiple global sites.
With Veeva’s modules, ARG reduced administrative friction, improved document version control, and condensed trial timelines.
This case demonstrates how Veeva’s software becomes operational leverage for CROs, not just pharma sponsors. It also shows expansion potential: using clinical modules is often the first step for newer customers, which can later lead to adoption of regulatory or quality modules (i.e. land & expand).
Takeaway: Modular deployment in clinical workflows can act as an entry wedge; once workflows are validated, Veeva can upsell downstream modules.
Case Study: Bayer AG — Omnichannel Marketing & Data Platform
“We’re bringing patient and caregiver communication into the mix … we think it will have a big impact.” — Nick Lucente, Senior Director Oncology Digital Marketing, Bayer
Bayer leveraged Veeva Crossix & Veeva CRM to connect HCP + patient and digital-field workflows across channels.
The use case highlights how Veeva’s Data Cloud and analytics modules extend beyond R&D into Commercial execution—a key growth driver.
Demonstrates cross-sell opportunity and stickiness when a pharma uses both commercial data + field workflows on one platform.
Reinforces our “brand power & network effect” moat angle.
Strategy and Moat
Veeva’s strategy is rooted in a simple but powerful principle: dominate a vertical by building the deepest, most compliant, most indispensable solutions, then expand adjacently across that vertical’s value chain. Unlike horizontal SaaS players who risk commoditization, Veeva chooses specialization. Its execution has centered on:
Expanding from sales/marketing (Commercial Cloud) into R&D, regulatory, and quality (Vault).
Developing proprietary platforms (Vault) to reduce dependency on Salesforce.
Extending from workflows to data products (Link, Data Cloud).
Targeting expansion into adjacent regulated industries such as consumer goods and chemicals.
This layered strategy both deepens customer entrenchment and broadens the total addressable market.
Moat analysis
Evaluating competitive advantages through the lens of economic moats reveals strengths in several areas, ranked on a scale of 1 (weak) to 5 (strong):
Switching Costs (5): Once trial data, regulatory submissions, and safety records are embedded in Vault, switching vendors is virtually impossible without risking compliance breaches. Example: Gilead’s multi-year commitment to Vault CRM highlights the prohibitive costs of leaving. Net Revenue Retention (NRR) >120% confirms strong expansion dynamics.
Cost Advantage (3): SaaS inherently scales well, but Veeva’s cost advantage is not in raw pricing; rather, it lies in lower compliance costs for customers. By using Veeva, pharma firms reduce the need for custom IT builds and mitigate regulatory risk. However, competitors like IQVIA also leverage scale in data aggregation.
Regulatory Barriers (4): Veeva designs systems that meet stringent FDA/EMA/ICH standards. Any competitor must replicate not only the functionality but also the documented validation processes.
Its Public Benefit Corporation (PBC) status signals alignment with regulatory and societal expectations, further strengthening trust.
Brand Power (4): Among life sciences companies, Veeva has become nearly synonymous with compliance-grade cloud software. Its reputation is strongest in large pharma (19 of top 20 are customers). For newer markets (consumer goods, chemicals), brand equity is not yet established.
Intellectual Property (3): The core IP is not patents but domain-specific workflow expertise encoded in software. Vault’s architecture is proprietary, but in principle, workflows could be rebuilt. The moat here is weaker than switching costs or regulatory trust.
Network Effects (2): Veeva benefits modestly from network effects in data products (Link, Data Cloud), where more users improve data accuracy.
However, the core SaaS products are not true network platforms. Value does not compound significantly as more customers join.
Building the Moat Through Product Expansion
Veeva has actively expanded its moat through targeted product additions. From 2015 to 2020, Veeva systematically added new applications: Veeva Network for master data management, Crossix for marketing analytics, Link for KOL (key opinion leader) engagement, and most recently, Veeva Data Cloud. These moves broadened its suite while reinforcing the moat of integration and customer stickiness. Each new module increased switching costs, as customer data and compliance processes became more deeply embedded in the Veeva ecosystem.
Porter’s Five Forces
A Porter’s Five Forces analysis further contextualizes the strategy:
Threat of New Entrants (Low): The barriers to entry in life sciences software are extremely high. Vendors must meet strict FDA/EMA validation, master complex domain workflows, and earn deep trust with global pharma and biotech clients.
This makes true new entry (i.e., from startups or horizontal SaaS vendors) very unlikely. While large incumbents such as Salesforce (through its IQVIA partnership) and Oracle Health are credible competitors, they are existing players rather than new entrants. Their scale and distribution muscle reinforce competitive intensity (see “Competitive Rivalry”), but they do not increase the risk of new entrants.Threat of Substitutes (Moderate): Custom-built IT systems remain substitutes for some smaller biotechs, but large pharma is moving away from bespoke software.
The biggest substitute risk is staying on Salesforce with IQVIA data overlays.
Buyer Power (Low/Moderate): Pharma companies are large and sophisticated, but their risk aversion lowers bargaining leverage. Since no single customer exceeds 10% of revenue, concentration risk is modest.
Supplier Power (Low): Veeva’s main “suppliers” are cloud infrastructure providers (AWS, Azure), where it has bargaining leverage as a scale SaaS. Talent is the other supplier: engineering and domain experts are critical, but compensation strategy (equity-heavy) helps retain them.
Competitive Rivalry (Moderate/High): Veeva faces entrenched competition from IQVIA (partnered with Salesforce), Oracle Health, and specialized niche players in data or clinical management. IQVIA leverages deep data assets and Salesforce’s CRM stack, while Oracle’s legacy systems maintain large installed bases. Yet Veeva’s domain-specific design and single-platform Vault architecture give it strong differentiation. Customer switching is rare once Vault is embedded, keeping churn low despite headline competition.
Supply-Side Dependencies
Veeva’s supply chain is straightforward compared to physical businesses, but there are dependencies:
Cloud Infrastructure: Hosted primarily on AWS, though multi-cloud strategies reduce risk. Bargaining power lies with Veeva given scale and mission-critical workloads.
Human Capital: Domain expertise in life sciences is non-negotiable. Recruiting scientists, regulatory experts, and engineers is vital. This creates competition with biotech firms and other SaaS companies for talent.
Third-Party Data Providers: For Data Cloud, partnerships with external data suppliers complement proprietary datasets. Any disruption could affect product completeness.
Strategic Priorities
Vault Expansion: The core growth driver. Every new Vault module (e.g., Safety) expands wallet share and increases customer stickiness.
CRM Migration: A risky but necessary move. Strategic independence from Salesforce ensures long-term control.
Data Cloud & Link: Position Veeva as not just a workflow provider but a data intelligence platform.
Industry Diversification: Initial experiments in consumer products and chemicals could double TAM, but require careful cultural and product adaptation.
Achieving Platform Independence: CRM Migration
A key strategic priority is the ongoing migration of CRM off Salesforce’s platform and onto Vault infrastructure. The move was driven by both strategic independence and the desire to unify all of Veeva’s offerings on a single underlying platform. The migration was not without risk: customers were accustomed to the Salesforce-based system, and competitors such as IQVIA partnered with Salesforce to launch alternative solutions. Nonetheless, Veeva believed that controlling its own technology stack was essential for long-term innovation and profitability. This migration is still ongoing and remains a focal point of investor discussions. Let’s dig in a bit more why this is still a focal point:
Strategic Upside (Why It Could Benefit Veeva)
Platform control = higher margins & innovation speed: By moving from Salesforce’s platform to its own Vault architecture, Veeva eliminates recurring licensing fees and dependency on another company’s roadmap. Over time, this improves gross margins and lets them innovate faster, adding AI, analytics, and data integrations purpose-built for life sciences.
Unified ecosystem: Having CRM, content (Vault), and data products on one platform means tighter integration, lower maintenance for customers, and a stronger moat. It’s similar to what Microsoft achieved with its unified stack.
Long-term differentiation: Competitors like IQVIA still depend on Salesforce, so Veeva’s independence could become a structural advantage if the migration succeeds smoothly.
Execution Risk (Why Investors Are Watching Closely)
Migration complexity: Thousands of pharmaceutical field reps and medical liaisons worldwide rely on Veeva CRM daily. Transitioning them to a new platform without disruption is technically and operationally difficult.
Timing and adoption: The full migration is taking years, and investors are monitoring whether customers will re-sign with Veeva once their Salesforce contracts expire (some extend into 2025–2026).
Competitive window: The slower the transition, the more time competitors (especially IQVIA + Salesforce) have to poach clients or position alternatives.
In short: it’s a focal point because the stakes are high on both sides. Success would strengthen Veeva’s strategic independence and profitability; delays or customer churn could dent near-term growth and sentiment.
Independence from Salesforce
A significant turning point arrived in 2021 when Veeva announced plans to migrate its CRM from Salesforce’s platform to Vault CRM. This strategic move underscored the company’s long-term ambition to control its full technology stack. While the transition carried risks, customer resistance, execution challenges, it reflected confidence in Vault’s maturity and Veeva’s ability to stand fully on its own.
Long-Term Vision
Gassner often emphasizes that Veeva is “built to last 100 years.” This philosophy translates into steady execution, patient capital allocation, and a refusal to chase fads. The PBC designation underscores this vision, aligning long-term strategy with broader stakeholder trust.
For investors, the key takeaway is that Veeva’s strategy is both defensive (moats, stickiness, regulatory barriers) and offensive (expanding TAM, moving into data, diversifying industries).
Customer base
Who Are the Customers?
Veeva’s customer base is concentrated in one vertical: life sciences. As of 2025, the company serves over 1,000 organizations, including 19 of the top 20 global pharmaceutical companies. The rest of the base consists of mid-sized pharma, biotech startups, contract research organizations (CROs), and, increasingly, adjacent regulated industries such as consumer goods and chemicals.
The decision-makers are typically senior executives in commercial, regulatory, or R&D functions. For example:
Chief Medical Officers and clinical operations leaders choose Vault Clinical.
Regulatory affairs executives rely on Vault Regulatory.
Chief Commercial Officers select CRM and Commercial Cloud products.
Quality directors manage manufacturing and lab workflows with Vault Quality.
This concentration of decision-making at the executive level underscores Veeva’s position as a must-have enterprise platform, not a point solution.
Retention and Expansion
Customer loyalty is exceptionally strong. Veeva consistently reports net revenue retention (NRR) above 120%, meaning existing customers not only renew but expand their spend each year. Retention is supported by:
Mission-critical functionality — systems embedded in regulatory filings and clinical submissions cannot be turned off.
Expansion across modules — once a customer adopts one Vault product, it becomes natural to add others (Clinical → Quality → Regulatory).
Switching costs — migrating terabytes of regulatory data from Vault would entail enormous risk and expense.
While the majority of revenue is subscription-based and recurring (~80–85%), the non-recurring portion (professional services) is actually a growth signal, since service work usually precedes new product adoption.
Revenue Concentration
One key strength of Veeva’s base is diversification. No single customer accounts for more than 10% of revenue, and even the largest contracts with top pharma firms are spread across multiple geographies and business units. This reduces concentration risk and ensures no single client has undue bargaining power.
The customer mix also spans the industry lifecycle: large pharma provides stable, long-term revenue, while biotech startups contribute growth but with higher churn. CROs are another growing segment, using Vault to streamline operations for their own clients.
Given the lack of granular segmentation, one can only estimate the split. Based on cues:
Because Veeva highlights having both large pharma and “emerging” biotech clients, the mix likely leans toward enterprise / large pharma as the majority — partly because large players have deeper pockets, multi-module needs, and more stable funding.
The fact that no single customer exceeds 10% of revenue suggests Veeva avoids overdependence on any one large pharma, but that doesn’t imply the count of enterprise vs biotech is balanced.
The number of customers (1,477) suggests many customers are smaller — so even if many are emerging biotechs, they may represent a smaller share of revenue.
A plausible rough assumption might be 20–40% of customers are emerging biotech / growth-stage companies, with 60–80% being mid/large pharma, but that is speculative.
Geographic Reach
Veeva has built a global footprint to follow its customers. Revenue distribution is approximately:
North America: ~55%
Europe: ~30%
Asia-Pacific and Rest of World: ~15%
This global spread reflects the fact that drug development and commercialization are increasingly international. Regulatory filings often require simultaneous submissions to multiple agencies, and Veeva’s platform supports this complexity. Local sales teams and services staff support adoption in markets like Japan, China, and India.
The “Must-Have” Factor
Veeva’s solutions are not discretionary IT purchases; they are embedded in mission-critical workflows. For example:
A drug cannot move through Phase III trials without a compliant trial master file, which Vault Clinical manages.
Regulatory filings to the FDA or EMA require precise documentation stored and tracked in Vault Regulatory.
Quality issues in manufacturing, tracked in Vault Quality, can trigger product recalls if mishandled.
For customers, Veeva is not simply a productivity tool but a compliance safeguard. This gives the company resilience against budget cuts and downturns. Even in weaker biotech funding cycles, clients are reluctant to remove or replace Veeva systems once implemented.
Case Study: Biotech Expansion
A mid-sized biotech developing oncology therapies illustrates the expansion path. Starting with Vault Clinical for trial management, the company added Vault Regulatory as it prepared for FDA submissions. Post-approval, it layered on Vault Quality for manufacturing oversight. Within five years, Veeva’s ACV with this single client expanded more than 3x, all while reducing compliance risk. This type of land-and-expand story is common and explains why NRR exceeds 120%.
Customer Risks
There are, however, risks in the customer base:
Smaller biotech churn: Biotechs reliant on venture funding may cancel or delay projects in downturns.
CRM migration uncertainty: Some commercial clients are cautious about leaving Salesforce for Vault CRM. Competitors like IQVIA-Salesforce could peel away new deals.
Expansion to new industries: While life sciences adoption is proven, success in consumer goods or chemicals is not guaranteed. Cultural differences in those industries may challenge Veeva’s sales approach.
Summary
Veeva’s customer base is broad, diversified, and sticky. With >1,000 clients across the pharma value chain, 120%+ NRR, and no single customer concentration, the business enjoys both stability and growth. The “must-have” nature of its products means Veeva occupies a privileged position in IT budgets, especially in large pharma. Expansion into adjacent industries offers upside, though execution risk remains.
For investors, the strength of the customer base is one of the clearest validations of the durability of the business model.
Industry Context
Market Structure
Veeva operates at the intersection of enterprise SaaS and life sciences IT, a market that is both massive and highly specialized. Global pharma and biotech companies collectively spend tens of billions annually on IT systems, spanning R&D, regulatory, commercial, and data analytics. Unlike most enterprise software categories, this is not a fragmented SMB market but an oligopoly-like environment: a few large vendors dominate, while barriers to entry are high due to regulatory complexity.
The industry can be divided into three main competitive domains:
Commercial CRM and marketing solutions.
Content and regulatory platforms for R&D and compliance.
Data and analytics providers.
Veeva has built leadership in the first two and is pushing into the third, where incumbents are entrenched.
Competitors
The competitive landscape features a mix of direct rivals, partial substitutes, and potential disruptors:
IQVIA: The most formidable competitor, especially in data and analytics. IQVIA combines clinical trial services, real-world data, and analytics into a massive offering. Its partnership with Salesforce to launch life sciences CRM poses the most direct threat to Veeva’s Commercial Cloud. Still, IQVIA lacks a true equivalent to Vault, where Veeva’s advantage is strongest.
Salesforce: Once an enabler through its Force.com platform, Salesforce is now a competitor via the IQVIA alliance. However, Salesforce’s horizontal DNA limits its ability to specialize at the depth Veeva requires.
Oracle: Competes in clinical trial management systems through its acquisition of Phase Forward and Cerner. Oracle’s solutions are older, more fragmented, and less cloud-native than Veeva’s, but its deep customer base remains relevant.
Medidata (Dassault Systèmes): A strong competitor in clinical trial software. Medidata’s Rave EDC (electronic data capture) system remains widely used. However, Medidata has struggled to match Vault’s breadth across regulatory and quality domains.
Smaller Niche Vendors: Companies like ArisGlobal, Sparta Systems (acquired by Honeywell), and MasterControl compete in specific niches like safety or quality management. These players often focus on SMB biotechs or mid-sized pharma but rarely challenge Veeva in global accounts.
Market Share and Positioning
Veeva’s share of the life sciences SaaS market is difficult to quantify, but several data points illustrate its leadership:
In Commercial Cloud CRM, Veeva commands ~80% share among large pharma salesforces, far outpacing IQVIA/Salesforce.
In Vault Regulatory Information Management, over 450 companies use its solutions, making Veeva the de facto standard.
In Quality and Clinical, Vault adoption continues to expand, though Medidata and Oracle retain footholds.
In data, however, IQVIA dwarfs Veeva. IQVIA’s datasets are unmatched in scale, and while Veeva Data Cloud is growing, it remains a challenger. Veeva’s strategy is not to replicate IQVIA’s breadth but to integrate data directly into workflows, creating a stickier combined product.
Industry Trends Favoring Veeva
Several macro trends reinforce Veeva’s positioning:
Shift to Cloud: Life sciences companies historically relied on on-premise, bespoke IT. The pandemic accelerated cloud adoption, and regulatory bodies now encourage electronic submissions. Veeva, as a cloud-native vendor, is a natural beneficiary.
R&D Complexity: Drug development costs are rising, with trials spanning more sites, more data, and tighter regulations. Tools like Vault Clinical and Vault Quality directly address these challenges.
Globalization of Pharma: As companies expand trials into Asia and emerging markets, compliance complexity multiplies. Veeva’s globalized, validated cloud is better suited than local IT teams patching together solutions.
Data as Competitive Edge: Pharma firms increasingly compete on data insights, not just molecules. This underpins the rationale for Veeva Data Cloud and Link.
Industry Consolidation: M&A in pharma drives demand for standardized platforms. A merged entity adopting different IT systems often consolidates onto Veeva Vault.
Risks from Industry Dynamics
The industry context also highlights risks:
Rival Platforms: If Salesforce-IQVIA CRM gains traction, Veeva’s dominance in Commercial Cloud could erode. This is the most visible competitive battle.
Data Scale: Competing with IQVIA in real-world data will require significant investment. Veeva risks being a niche player unless it scales quickly.
Regulatory Changes: Stricter or shifting rules could create both opportunity (need for new modules) and risk (compliance costs).
Tech Giants: Microsoft, Google, or Amazon could enter regulated vertical SaaS with cloud-native products. While unlikely in the short term, their scale could challenge Veeva in the long run.
Comparisons to Broader SaaS
Relative to horizontal SaaS peers, Veeva’s model is unusual:
Profitability: Few SaaS companies maintain net margins >25% while still growing >15%. Veeva consistently does.
Valuation: At ~35x forward FCF, Veeva trades at a premium to peers like Salesforce (~20x) or ServiceNow (~28x), but a discount to its pandemic peak multiples (>70x).
Durability: The vertical SaaS model, coupled with life sciences’ inelastic IT demand, makes Veeva more durable than most enterprise SaaS firms.
Industry Outlook
Analyst reports project the life sciences IT market to grow at ~12–15% CAGR over the next five years. Drivers include clinical trial digitization, regulatory modernization, and rising biologics pipelines. This aligns closely with Veeva’s own growth guidance, which is close to 17% CAGR.
Veeva’s challenge will be balancing its dominance in a niche with expansion into new markets. If it can replicate Vault’s success in adjacent industries, growth could accelerate. If not, it risks being boxed into life sciences, a market it already heavily penetrates.
Summary Industry Context
The industry context reveals both why Veeva has flourished and what it must overcome:
It dominates life sciences SaaS in CRM and regulatory/quality.
It faces serious competition in data from IQVIA.
The cloud migration trend, regulatory complexity, and pharma globalization all favor its model.
However, valuation demands that it expand beyond its current base to sustain growth.
For investors, the competitive backdrop is supportive, but the question is whether Veeva can leverage its position to win in data and adjacent industries without diluting focus.
Growth Drivers
Expansion of Vault
The single biggest growth driver remains Vault adoption and expansion. Veeva has steadily transformed Vault from a content management system into an end-to-end platform covering clinical, quality, regulatory, and safety functions. Each module a customer adopts increases average contract value and embeds Veeva deeper into workflows.
For example, a mid-sized biotech might start with Vault Clinical to manage trial master files. As it approaches regulatory submission, it adds Vault Regulatory. Once the drug is approved, it rolls out Vault Quality to oversee manufacturing compliance, and later Vault Safety to track adverse events. Each step adds revenue streams and increases switching costs.
Because pharma pipelines are continuous and multi-year, the opportunity for expansion within existing customers is durable. Analysts estimate Vault penetration is still only 30–40% of its full TAM, leaving room for significant growth.
CRM Migration and Renewal
Although CRM is a mature product, the migration off Salesforce represents both a risk and a growth lever. If executed successfully, Veeva can increase margins by eliminating Salesforce licensing costs and creating a unified platform across CRM and Vault. Customers who follow Veeva to Vault CRM will further lock in, reducing reliance on third-party infrastructure.
Additionally, CRM contracts provide ongoing opportunities for upsell via digital engagement tools like Engage Meeting and Approved Email, which grew sharply during COVID-19 and remain part of hybrid salesforce strategies.
Data Cloud and Link
The next frontier is data and analytics. While Veeva’s workflow products generate stable cash flows, the data market offers incremental growth.
Veeva Data Cloud provides longitudinal patient and prescriber data. Though IQVIA remains the incumbent, customers value having integrated data inside the same workflows where they run trials and regulatory submissions.
Veeva Link builds networks of medical experts and scientific influencers, helping clients identify key opinion leaders for drug launches.
If these products capture even modest share, they could grow into billion-dollar businesses. The combination of workflow + data creates a differentiated proposition IQVIA cannot fully replicate, since its data is often standalone.
Geographic Expansion
Pharma is increasingly global. Trials in Asia-Pacific, submissions to regulators in China or Brazil, and global supply chains demand consistent compliance platforms. Veeva has expanded operations in Europe and Asia, and is investing in localized versions of Vault to meet country-specific regulations.
This geographic growth contributes both to new logo wins and upsells for global deployments. For example, a U.S.-based pharma may roll out Vault Clinical in North America, then expand to Europe and Asia to harmonize trial management globally.
Pricing Power
Though Veeva does not emphasize aggressive pricing, its products exhibit pricing power because they are mission-critical. Price increases are often accepted because alternatives are riskier and more costly in compliance terms. While unit pricing may not rise dramatically, expansion across modules effectively increases customer spend.
Adjacent Industries
Veeva has begun targeting other regulated verticals, including consumer goods, chemicals, and cosmetics. These industries also face quality management and regulatory documentation challenges, though the stakes are less existential than pharma drug approvals. Success here could expand TAM materially, though execution risk remains high.
The opportunity is particularly strong in quality management, where Vault Quality could serve as a cross-industry compliance platform. Early wins in consumer products validate the potential.
M&A
Historically, Veeva has been conservative in acquisitions. It prefers to build rather than buy. However, small tuck-ins, especially around data, could accelerate growth. Acquiring niche datasets or analytics capabilities would bolster Veeva Data Cloud, helping it compete more effectively with IQVIA.
AI as a Growth Catalyst
Veeva’s latest investor presentations emphasize AI as a driver of both efficiency and expansion. Within Vault, AI models are being embedded for intelligent document processing, metadata extraction, and predictive compliance checks. In Data Cloud and Link, AI enhances relationship mapping, scientific insight generation, and trial site optimization. These initiatives are early but could lift growth toward the high end of management’s 17% CAGR trajectory if adoption accelerates across enterprise accounts.
Long-Term Guidance
Management has guided to mid-teens revenue growth for the next two years, and recently outlined a long-term revenue target of $6 billion by FY2030, implying a ~17% CAGR from FY2026–FY2030. This sits above our 13–15% conservative base case and suggests meaningful upside if AI-driven automation and new product modules scale as intended.
Veeva’s Q2 FY 2026 results delivered 17% year-over-year growth in revenue, and management updated FY 2026 guidance to $3,134M–$3,140M, with non-GAAP operating income of ~$1,388M. In the Q1 FY 2026 release, the company expected revenue of $3,090M–$3,100M and EPS of ~$7.63.
Taken together, a long-term model assumption of 13–15% CAGR lies between management’s near-term guidance and historical performance, making it a prudent conservative case rather than an optimistic stretch.
Recent Expansions and Challenges
In recent years, Veeva has expanded beyond life sciences into other regulated industries such as consumer products and chemicals, though life sciences remains the vast majority of revenue.
It has also invested heavily in data and analytics, launching Veeva Data Cloud and Veeva Link, which provide longitudinal patient and physician data as well as scientific relationship networks. These products extend Veeva’s role from a workflow enabler to a data provider, competing with incumbents like IQVIA but leveraging its strong customer relationships to win market share.
Despite these successes, challenges have emerged. The CRM migration has created uncertainty, some new modules have faced slower adoption, and the valuation multiples attached to Veeva stock have compressed from their 2020–2021 highs.
Nonetheless, the company’s strategic direction remains intact: expand its footprint across the drug development lifecycle, leverage proprietary platforms, and continue delivering durable, highly profitable growth.
Summary Growth Engine
The growth engine is multi-faceted:
Vault expansion remains the dominant lever.
CRM migration could unlock margin gains and customer stickiness.
Data Cloud and Link offer long-term upside in analytics.
Geographic expansion broadens deployment opportunities.
Adjacency into other industries could materially increase TAM.
Selective M&A provides optionality in data.
AI a driver of both efficiency and expansion
For investors, the key question is whether Veeva can sustain double-digit growth long enough to justify its premium valuation. The ingredients are in place, but execution on Data Cloud and CRM migration will determine whether growth surprises on the upside.
Financial model & Valuation
Recent Performance
Recent performance shows revenue reaching $2.7 billion in fiscal 2025 with free cash flow margins close to 45%. Veeva now serves more than 1,000 customers, including 19 of the top 20 global pharmaceutical companies, and enjoys net revenue retention consistently above 120%. Importantly, no single customer accounts for more than 10% of revenue, reducing concentration risk.
The story of Veeva’s evolution is one of deliberate focus, disciplined execution, and widening competitive advantage. From a single CRM application built on someone else’s platform, it has grown into a diversified, independent ecosystem for regulated industries. Each stage of this evolution, from IPO, Vault expansion, diversification to Salesforce independence, reinforced its reputation as one of the most durable and predictable business models in enterprise software.
Veeva’s economics are best captured through its cash flow. For the last twelve months:
Revenue: $2.97B
Gross Margin: 75.6% - a hallmark of mature SaaS companies
Operating Margin: 28%
Net Margin: 27.3%
Free Cash Flow Margin: 44.7% - minimal capital expenditures needs and efficient working capital dynamics (large upfront billings through unearned revenue).
Cash from operations is $1.35B, while CapEx is minimal (<2% of revenue, often not broken out because it’s so small). Veeva consistently converts more than 100% of net income into free cash flow, thanks to high deferred revenue balances and low reinvestment requirements. Share-based compensation (SBC) was ~$467M, about 16% of revenue. On an owner’s earnings basis (OCF – SBC – CapEx), Veeva generated ~$870M. This aligns with the valuation multiples (P/FCF ~34x).
Veeva’s free cash flow has compounded from ~$550 M in FY 2020 to ~$1.35 B for the last twelve months, underscoring its capital-light model and 40 %+ FCF margins.
The balance sheet is pristine: nearly $6.4 billion in cash and investments, no debt, and steady share count growth only modestly offset by repurchases. Capital allocation is conservative: no dividend, limited buybacks, and no large acquisitions. Instead, management reinvests in R&D (~25% of revenue) to expand Vault modules and AI-driven analytics.
Owner’s Earnings Model
Owner’s earnings adjusts free cash flow to reflect the economic cost of SBC:
Operating Cash Flow: $1.35B
CapEx: ~0 (minimal)
SBC: $467M
Owner’s Earnings: ~$883M
This suggests that traditional FCF overstates distributable cash because it ignores dilution from SBC. At a market cap of ~$46B, Veeva trades at ~52x owner’s earnings.
While traditional free cash flow paints Veeva as comfortably profitable, adjusting for SBC reveals that true distributable cash is meaningfully lower. At roughly 52× owner’s earnings, the stock prices in a long runway of double-digit growth and disciplined dilution control, expectations that leave little room for execution missteps.
Reverse DCF
With a stock price of ~$285 (October 30, 2025) and a market cap of ~$46.7B, what growth is implied? Assuming:
Discount rate: 10%
Terminal growth: 2.5%
Cash flow CFO: 1.35B
Owner’s Earnings: $883M
I rhink using Owner’s Earnings DCF is the cleanest, most Buffett-aligned way to handle SBC in my Veeva model without forecasting share count growth. This means SBC is treated as a real economic cost, just like a cash expense, even though it’s non-cash. For year 1 I will take the expected Owners Earnings FCF for next year, which I forecast at $883M * 1.17 = $1,033.
At ~$289 a share the implied 10 year FCF CAGR is 20.4% to achieve a 10% required return. This feels like a sporty valuation given their own expectations closer to 17%.
Discounted Cash Flow
In the discounted cash flow I will discuss the outcome of:
the conservative scenario where I will take the mid of the 13-15% range, so 14%
the base case of 17% growth
the opportunistic case with 19% growth
Base case (~17% growth): the stock is overvalued by 19.7% to get an annual return of 10%, and this doesn’t give even include a margin of safety.
Conservative case (~14% growth): the stock has an overvaluation of 33.5% and shows an intrinsic value of $192.1 to get to a 10% annual return
Opportunistic case (19% growth): the stock is 8.8% overvalaued and the intrinsic value is $263.6.
So for none of the scenario’s the current valuation seems justified. As I always prefer a margin of safety, I would go with the conservative case to determine my buy below price, and hence I will take $192.1 which gives a stronger margin of safety. My corresponding annual expected return for the next ten years would be 12%.
Forward P/E and FCF yield
Comparing the forward P/E by the historical trend tells us a bit more about current valuation. Current forward P/E is at 35.8 versus a median of 53.2 the last ten years. A forward P/E of 53.2 is really high and even 35.8 is still at the high end, so it confirms my DCF calculation seeking for a bit more margin of safety.
For Veeva Systems the FCF yield chart shows a stable path between 1-4% over the past decade, with a median of 2.2% and a current yield of 2.9%. For context, the 10-year US Treasury bond yield stands at ~4.2%. So this indicator also shows the current stock price seems to be at the high end.
Risks Tied To The Model
Execution Risk: CRM Migration
Veeva’s CRM is still tied to Salesforce for many customers, though the company is building its own Vault CRM. The migration is a double-edged sword:
Upside: eliminates Salesforce licensing costs, improves integration.
Downside: execution missteps could result in customer churn, delays, or cost overruns. If Salesforce attempts to compete more aggressively, pricing pressure could also emerge.
Severity: High. CRM contributes ~40% of revenues and serves as the “front door” into accounts.
Competitive Risk: IQVIA and New Entrants
The data market is dominated by IQVIA, which has entrenched relationships with pharma. While Veeva’s Data Cloud and Link offer integrated workflows, gaining share is not guaranteed. If IQVIA aggressively defends its turf through bundling, Veeva could face slower adoption or pricing concessions.
In workflow software, competitors like Medidata (Dassault Systèmes) and Oracle Health Sciences also play in clinical and trial management. Though less integrated, they remain alternatives for certain customers.
Severity: Medium. Veeva has strong incumbency, but data and analytics expansion is a head-to-head fight.
Customer Concentration and Pharma Cyclicality
While Veeva serves more than 1,000 customers, 19 of the top 20 global pharma companies anchor its revenue base. If a large customer (say Pfizer or GSK) decided to shift budgets, the impact could be material. In addition, biotech funding cycles are cyclical; downturns in biotech capital raising could slow adoption of Vault Clinical and related modules.
Severity: Medium. Concentration is real, but diversification across many functions and customers mitigates this.
Regulatory and Compliance Risk
Because Veeva operates in highly regulated industries, its products must continuously comply with global regulatory frameworks (FDA, EMA, ICH, etc.). Any failure in Vault modules, e.g. in regulatory submissions, clinical trial data integrity, pharmacovigilance, or quality management, could lead to regulatory sanctions, reputational damage, or customer churn. Veeva itself discloses that
“changing laws and regulations … may impose additional costs for compliance, reduce demand for our solutions, and subject us to significant liabilities.” - SEC
Privacy and data protection rules (GDPR, HIPAA, cross-border data localization laws) create additional complexity. The expansion into patient data with Veeva Data Cloud increases exposure, since handling longitudinal patient and prescriber data magnifies the need for strong privacy controls and regulatory safeguards.
In an earlier filing, Veeva notes that the cost of subscription services has increased over time due to rising employee compensation, computing infrastructure, and data costs tied to growing user base and data processing. This suggests that part of the compliance burden (e.g. infrastructure for audit trails, secure data handling) is already baked into operating expenses.
Because these regulatory burdens are ongoing, evolving, and often opaque in advance, we rate the severity as High. It is a constant tail risk and operating burden that must be managed diligently.
Financial Risk: SBC and Dilution
Veeva’s free cash flow generation remains strong, but stock-based compensation (SBC) is a double-edged sword. Over the last twelve months, SBC totaled $467 million, roughly 15.7% of revenue and 35% of operating cash flow. The company’s equity-driven pay structure aligns management closely with long-term shareholders. Executives earn relatively modest base salaries and no cash bonuses, instead receiving equity that vests over multiple years. This fosters a durable, ownership-oriented culture and helps retain key leaders.
However, the economic impact is still tangible. SBC represents a recurring cost of doing business and leads to gradual dilution. Veeva’s share count has risen from 152 million in FY 2020 to 164 million today, growing about 1.5% annually. SBC is a steady 13–16% of revenue, with dilution flattening in recent years. This is evidence of tighter grant discipline and occasional offsetting buybacks.
Even so, persistent SBC at this level means “owner’s earnings” (free cash flow minus SBC) will expand more slowly than reported FCF. While the cultural and incentive alignment is a clear strength, from a valuation perspective, it remains one of the most significant headwinds to per-share value creation.
Severity: High. SBC enhances alignment but weighs on true per-share compounding; Veeva’s challenge is maintaining cultural strength while reducing dilution over time.
Valuation Risk
At ~$289/share, Veeva trades at ~57x trailing earnings and ~34x FCF. Even with strong growth, these multiples imply sustained double-digit expansion for 10 years. If growth slows to high single digits, multiples could compress sharply.
Severity: High. Valuation risk is acute given premium multiples.
Talent and Culture
Veeva’s “team-first” culture, modest base salaries, and equity-heavy compensation align employees with long-term outcomes. However, the tech labor market is competitive, and reliance on equity incentives may weaken if stock performance stalls. Turnover at the executive level, such as the recent CFO transition, adds potential disruption.
Severity: Medium. Mitigated by strong cultural cohesion but dependent on equity value.
Operational Risk: Cloud Infrastructure
As a SaaS company, Veeva depends on cloud infrastructure uptime. Outages or cybersecurity breaches could damage trust, especially since Vault houses mission-critical regulatory documents. The migration off Salesforce also increases internal responsibility for reliability.
Severity: Medium. Standard SaaS risk, but stakes are higher in life sciences.
Geographic and Political Risk
International expansion into Asia and Europe exposes Veeva to local regulations, data sovereignty laws, and political risk. For instance, China’s tightening of data localization could limit adoption of Veeva Data Cloud. Geopolitical tensions could also impact multinational deployment.
Severity: Low-to-Medium. Diversification reduces but does not eliminate this risk.
Summary of Risk Profile
High Severity Risks: CRM migration, regulatory compliance, stock-based compensation/dilution, valuation.
Medium Severity Risks: Competition, customer concentration, talent retention, operational reliability.
Low-to-Medium Severity Risks: Geographic and political expansion.
Overall, Veeva carries execution and valuation risk more than financial health risk. The balance sheet is pristine, with $6.4 billion in cash and no debt. Thus, downside scenarios center on growth sustainability and shareholder dilution rather than solvency.
Investor Takeaways
After evaluating Veeva Systems across its history, management quality, culture, business model, strategy, customers, industry positioning, growth drivers, risks, and financial evolution, we can distill the analysis into five core investor takeaways.
1. Core Strength: Mission-Critical SaaS With High Switching Costs
Veeva’s moat is among the strongest in vertical SaaS. Its Vault platform underpins regulatory submissions, quality control, safety reporting, and clinical operations for nearly every major pharmaceutical company worldwide. Once embedded, switching is nearly impossible without jeopardizing compliance. This produces net revenue retention above 120% and ensures durability of revenue.
2. Key Dependency: Life Sciences Industry Growth
Although Veeva has begun expanding into adjacent regulated industries, its core business remains tethered to biopharma. Roughly 80–85% of revenues are tied to life sciences. If R&D pipelines slow, drug approvals decline, or regulatory structures change, Veeva’s growth could moderate. Diversification efforts into consumer goods and chemicals are still small.
3. Top Growth Driver: Expansion of Vault and Data Cloud
Vault continues to add new modules — clinical trial management, regulatory information management, quality documentation, and safety systems — each of which deepens customer reliance. The Data Cloud and Link initiatives are layering in analytics, AI, and real-world evidence datasets, which could create a second engine of growth over the next five years. Cross-selling remains powerful: most customers start with one module and expand into multiple.
4. Main Risk: Valuation and Share-Based Compensation
The company’s quality is not in doubt — but at ~34x forward free cash flow and ~35x forward earnings, the stock requires sustained double-digit growth for a decade. If growth slows toward mid-single digits, multiples will compress. Additionally, share-based compensation (~$470 million in FY2025) is material. While normalized free cash flow is strong, dilution remains a real concern for shareholders.
5. Biggest Unknown: AI’s Role in Future Growth
Veeva is investing heavily in AI-driven insights, data harmonization, and intelligent document processing. While this could enhance stickiness and create new revenue streams, the timing and magnitude are uncertain. If Veeva fails to monetize AI meaningfully, investors may reassess the growth story. Conversely, if AI modules become indispensable, growth could reaccelerate above expectations.
Final Conclusion
Veeva is one of the most durable SaaS businesses globally, but valuation and reliance on one vertical temper its score. We will have to wait for the stock price to come down to become an owner of this high quality SaaS company.
If you’d like to explore other companies and discuss on quality investing with fellow investors, join the Compound & Fire Discord community for free. We want to collaborate together and improve our knowledge in order to compound knowledge and investment returns! Thanks again for your contribution TuDi and Novo Nordisk is lined up to be the next deep dive.
Hopefully you have enjoyed this deep dive. Feel free to like the post and share it with friends!
Disclaimer
The information in this article is provided for informational and educational purposes only.
The information is not intended to be and does not constitute financial advice or any other advice, is general in nature, and is not specific to you. Before using this article’s information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence.
None of the information in this article is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. The author is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.
Great Deep Dive into Veeva — this company has one of the widest economic moats.
Great and very comprehensive article. Veeva share price has dropped now to ~ USD 200/share as of end Jan 26 near your conservative case. Any updated thoughts?